Sankalp India Foundation has marked an important milestone by signing a transformative Memorandum of Understanding with the Indian Red Cross Society, Andhra Pradesh, to establish a statewide network of Thalassemia and Sickle Cell Disease Day Care Centres. This phased initiative aims to strengthen structured, standardised management services for children and families affected by hemoglobinopathies across the state.
The partnership brings together complementary strengths. Sankalp will contribute its ThalCare digital platform, evidence-based treatment protocols, specialist clinical oversight, and clear pathways for advanced care, including bone marrow transplantation. The Indian Red Cross Society, Andhra Pradesh, will anchor these services through its strong on-ground infrastructure, trained clinical teams, and access to a safe and reliable blood supply. Together, the model enables precision transfusions, iron chelation therapy, diagnostics, prevention screening, and timely referrals for curative treatment.
For families living with thalassemia and sickle cell disease, consistent and high-quality management is the difference between survival and avoidable complications. By creating an organised day care network, this collaboration reduces fragmentation of care, improves adherence to treatment, and ensures that children receive comprehensive, lifelong support closer to home.
Beyond immediate clinical outcomes, the initiative addresses a larger systemic need. Strengthened management not only improves survival and quality of life but also creates the foundation for prevention and cure to succeed. With reliable data, standardised care, and integrated referral systems, the partnership lays the groundwork for long-term reduction in disease burden.
This collaboration sets a scalable blueprint for equitable hemoglobinopathy care in Andhra Pradesh. By breaking cycles of lifelong suffering and strengthening systems that place patients at the centre, Sankalp India Foundation and the Indian Red Cross Society, Andhra Pradesh, move the state closer to a future where thalassemia and sickle cell disease are effectively managed, prevented, and ultimately eliminated.